Search Medical Condition
Please enter condition
Please choose location

Schiedam, Netherlands Clinical Trials

A listing of Schiedam, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (187) clinical trials

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

0.0 miles

Learn More »

Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.

Although primary aldosteronism (PA) was formerly seen as a rare cause of hypertension, this condition is now thought to be the commonest cause of secondary hypertension, with the prevalence ranging up to 10-15 % of all hypertensives. Identification of patients with PA allows for specific treatment, for instance unilateral adrenalectomy ...

Phase N/A

0.0 miles

Learn More »

Clinical and Device Functional Assessment of Real World ICD Patients

For these reasons, it is very important to observe the clinical practice on a large variety of centers and countries, with the objective to collect long term safety and performance data in patients undergoing ICD/CRT-D device implantation (first implant, replacement or upgrade). The safety and performance of the ICDs can ...

Phase N/A

0.0 miles

Learn More »

Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

In preclinical studies the addition of bevacizumab to chemotherapy improves drug access in the tumor. In humans, bevacizumab monotherapy normalizes the tumor vascularization. It is presently unknown what molecular subtype would derive a progression free survival (PFS) benefit of the addition of bevacizumab to first line chemotherapy. There are indications ...

Phase

0.89 miles

Learn More »

Real-world Use of Carfilzomib Among Patients With Relapsed MM in Europe

With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data is available yet on how the drug is being used outside of the clinical trial setting. The Primary Objective is to describe carfilzomib utilisation in routine clinical practice, including dosage, administration schedule, regimen, duration of ...

Phase N/A

0.89 miles

Learn More »

An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol

ORION-3, an extension of study MDCO-PCS-15-01 (ORION-1) [NCT02597127], is a Phase II, placebo-controlled, double-blind, randomized trial to evaluate the efficacy, safety, and tolerability of inclisiran (ALN-PCSSC) injection(s). All participants who completed ORION-1 (at least up to and including Day 210) and meet the study criteria will be enrolled into this ...

Phase

2.66 miles

Learn More »